<p>结构治疗公司（NASDAQ:GPCR - 获取免费报告）周三的盘中交易中，股价上涨了 7.5%。该股最高交易价为 17.16 美元，最后交易价为 16.97 美元。盘中交易期间交易了 584,887 股，较 850,763 股的平均交易量下降了 31%。该股此前收盘价为 15.79 美元。</p>
<p>获取 <strong>结构治疗</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>罗氏能否在减肥市场挑战礼来和诺和诺德？</li>
</ul>
<p>几家券商最近对 GPCR 发表了评论。Stifel Nicolaus 在 1 月 8 日的研究报告中开始覆盖结构治疗公司。他们给予该公司 “买入” 评级，并设定目标价为 50.00 美元。JMP 证券在 12 月 18 日的研究报告中重申了 “市场表现优于大盘” 评级，并对结构治疗公司的股票设定了 91.00 美元的目标价。William Blair 在 2 月 28 日的研究报告中开始覆盖结构治疗公司。他们对该股给予了 “优于大盘” 的评级。最后，HC Wainwright 在 12 月 19 日的报告中重申了 “买入” 评级，并对结构治疗公司的股票设定了 80.00 美元的目标价。根据 MarketBeat 的数据，八位分析师对该股给予了买入评级，该公司的共识评级为 “买入”，平均目标价为 81.29 美元。</p>
<p><strong>阅读我们关于 GPCR 的最新股票报告</strong></p>
<h2>结构治疗股价下跌 7.4%</h2>
<ul>
<li>诺和诺德的挫折不会持续：一款改变游戏规则的药物出现</li>
</ul>
<p>该公司的市值为 8.6703 亿美元，市盈率为-20.43，贝塔值为-2.37。该公司的 50 日移动平均价格为 23.29 美元，200 日移动平均价格为 30.63 美元。</p>
<p>结构治疗公司（NASDAQ:GPCR - 获取免费报告）最近在 2 月 27 日发布了其财报。该公司报告季度每股收益为（0.22 美元），超出市场共识预期的（0.23 美元）0.01 美元。平均而言，卖方分析师预测结构治疗公司在当前财政年度的每股收益为-0.82 美元。</p>
<h2>机构投资者对结构治疗的看法</h2>
<ul>
<li>Altimmune 股票：它的 GLP-1 药物是下一个 Ozempic 杀手吗？</li>
</ul>
<p>几家机构投资者和对冲基金最近增加或减少了在 GPCR 的持股。Deep Track Capital LP 在第四季度将其在结构治疗公司的持股增加了 129.4%。Deep Track Capital LP 现在拥有 280 万股该公司的股票，价值 75,936,000 美元，此前在上个季度又购买了 1,579,492 股。Point72 Asset Management L.P.在第三季度将其在结构治疗公司的持股增加了 196.5%。Point72 Asset Management L.P.现在拥有 1,238,268 股该公司的股票，价值 54,348,000 美元，此前在上个季度又收购了 820,589 股。Vestal Point Capital LP 在第四季度将其在结构治疗公司的持股增加了 50.0%。Vestal Point Capital LP 现在拥有 1,725,000 股该公司的股票，价值 46,782,000 美元，此前在上个季度又购买了 575,000 股。Boxer Capital Management LLC 在第四季度购买了结构治疗公司的新股份，价值约为 13,560,000 美元。最后，Marshall Wace LLP 在第四季度将其在结构治疗公司的持股增加了 339.6%。Marshall Wace LLP 现在拥有 583,207 股该公司的股票，价值 15,817,000 美元，此前在上个季度又购买了 450,531 股。目前 91.78% 的股票由机构投资者持有。</p>
<h2>关于结构治疗公司</h2>
<p>（获取免费报告）</p>
<p>结构治疗公司是一家临床阶段的全球生物制药公司，开发并提供新型口服治疗药物，以治疗一系列未满足医疗需求的慢性疾病。该公司的主要产品候选药物是 GSBR-1290，一种口服和偏向性的小分子激动剂，针对的是胰高血糖素样肽-1 受体，这是一种经过验证的 G 蛋白偶联受体（GPCR）药物靶点，用于治疗 2 型糖尿病和肥胖症。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比结构治疗更好</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>上海证券交易所综合指数是什么？</li>
<li>做空者对这三只半导体股票是否错误？</li>
<li>在 52 周高点盈利交易股票</li>
<li>波音在 3 月份获得 500 亿美元订单——BA 股票现在值得买吗？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在结构治疗公司吗？</h2>
<p>在考虑结构治疗公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前...而结构治疗公司并不在名单上。</p>
<p>虽然结构治疗公司目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GPCR

<p>结构治疗公司（NASDAQ:GPCR）股价在午盘交易中上涨 7.5%，至 16.97 美元，成交量为 584,887 股。分析师对该股票给予了一致的 “买入” 评级，目标价格范围为 50 美元至 91 美元。该公司报告的季度每股收益为（0.22 美元），超出预期。机构投资者持有该股票的 91.78%，多家公司的持股显著增加。结构治疗公司专注于开发用于慢性疾病的口服治疗药物，包括 2 型糖尿病和肥胖症</p>

<p>Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report)'s stock price shot up 7.5% during mid-day trading on Wednesday . The stock traded as high as $17.16 and last traded at $16.97. 584,887 shares were traded during mid-day trading, a decline of 31% from the average session volume of 850,763 shares. The stock had previously closed at $15.79.</p>
<div class="lb-trans"><p>结构治疗公司（NASDAQ:GPCR - 获取免费报告）周三的盘中交易中，股价上涨了 7.5%。该股最高交易价为 17.16 美元，最后交易价为 16.97 美元。盘中交易期间交易了 584,887 股，较 850,763 股的平均交易量下降了 31%。该股此前收盘价为 15.79 美元。</p>
</div><p>Get <strong>Structure Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>结构治疗</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Can Roche Challenge Lilly and Novo in the Weight Loss Market?</li>
</ul>
<div class="lb-trans"><ul>
<li>罗氏能否在减肥市场挑战礼来和诺和诺德？</li>
</ul>
</div><p>Several brokerages have recently commented on GPCR. Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a &#34;buy&#34; rating and a $50.00 target price for the company. JMP Securities reiterated a &#34;market outperform&#34; rating and issued a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. William Blair initiated coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an &#34;outperform&#34; rating on the stock. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and an average target price of $81.29.</p>
<div class="lb-trans"><p>几家券商最近对 GPCR 发表了评论。Stifel Nicolaus 在 1 月 8 日的研究报告中开始覆盖结构治疗公司。他们给予该公司 “买入” 评级，并设定目标价为 50.00 美元。JMP 证券在 12 月 18 日的研究报告中重申了 “市场表现优于大盘” 评级，并对结构治疗公司的股票设定了 91.00 美元的目标价。William Blair 在 2 月 28 日的研究报告中开始覆盖结构治疗公司。他们对该股给予了 “优于大盘” 的评级。最后，HC Wainwright 在 12 月 19 日的报告中重申了 “买入” 评级，并对结构治疗公司的股票设定了 80.00 美元的目标价。根据 MarketBeat 的数据，八位分析师对该股给予了买入评级，该公司的共识评级为 “买入”，平均目标价为 81.29 美元。</p>
</div><p><strong>Read Our Latest Stock Report on GPCR</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 GPCR 的最新股票报告</strong></p>
</div><h2>Structure Therapeutics Trading Down 7.4 %</h2>
<div class="lb-trans"><h2>结构治疗股价下跌 7.4%</h2>
</div><ul>
<li>Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德的挫折不会持续：一款改变游戏规则的药物出现</li>
</ul>
</div><p>The stock has a market capitalization of $867.03 million, a P/E ratio of -20.43 and a beta of -2.37. The business has a 50-day moving average price of $23.29 and a two-hundred day moving average price of $30.63.</p>
<div class="lb-trans"><p>该公司的市值为 8.6703 亿美元，市盈率为-20.43，贝塔值为-2.37。该公司的 50 日移动平均价格为 23.29 美元，200 日移动平均价格为 30.63 美元。</p>
</div><p>Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, sell-side analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>结构治疗公司（NASDAQ:GPCR - 获取免费报告）最近在 2 月 27 日发布了其财报。该公司报告季度每股收益为（0.22 美元），超出市场共识预期的（0.23 美元）0.01 美元。平均而言，卖方分析师预测结构治疗公司在当前财政年度的每股收益为-0.82 美元。</p>
</div><h2>Institutional Investors Weigh In On Structure Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对结构治疗的看法</h2>
</div><ul>
<li>Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?</li>
</ul>
<div class="lb-trans"><ul>
<li>Altimmune 股票：它的 GLP-1 药物是下一个 Ozempic 杀手吗？</li>
</ul>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. Deep Track Capital LP raised its holdings in shares of Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after buying an additional 1,579,492 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Structure Therapeutics by 196.5% in the third quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company's stock worth $54,348,000 after acquiring an additional 820,589 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Structure Therapeutics by 50.0% in the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock valued at $46,782,000 after purchasing an additional 575,000 shares in the last quarter. Boxer Capital Management LLC bought a new stake in shares of Structure Therapeutics during the 4th quarter valued at approximately $13,560,000. Finally, Marshall Wace LLP increased its position in Structure Therapeutics by 339.6% during the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock worth $15,817,000 after purchasing an additional 450,531 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了在 GPCR 的持股。Deep Track Capital LP 在第四季度将其在结构治疗公司的持股增加了 129.4%。Deep Track Capital LP 现在拥有 280 万股该公司的股票，价值 75,936,000 美元，此前在上个季度又购买了 1,579,492 股。Point72 Asset Management L.P.在第三季度将其在结构治疗公司的持股增加了 196.5%。Point72 Asset Management L.P.现在拥有 1,238,268 股该公司的股票，价值 54,348,000 美元，此前在上个季度又收购了 820,589 股。Vestal Point Capital LP 在第四季度将其在结构治疗公司的持股增加了 50.0%。Vestal Point Capital LP 现在拥有 1,725,000 股该公司的股票，价值 46,782,000 美元，此前在上个季度又购买了 575,000 股。Boxer Capital Management LLC 在第四季度购买了结构治疗公司的新股份，价值约为 13,560,000 美元。最后，Marshall Wace LLP 在第四季度将其在结构治疗公司的持股增加了 339.6%。Marshall Wace LLP 现在拥有 583,207 股该公司的股票，价值 15,817,000 美元，此前在上个季度又购买了 450,531 股。目前 91.78% 的股票由机构投资者持有。</p>
</div><h2>About Structure Therapeutics</h2>
<div class="lb-trans"><h2>关于结构治疗公司</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.</p>
<div class="lb-trans"><p>结构治疗公司是一家临床阶段的全球生物制药公司，开发并提供新型口服治疗药物，以治疗一系列未满足医疗需求的慢性疾病。该公司的主要产品候选药物是 GSBR-1290，一种口服和偏向性的小分子激动剂，针对的是胰高血糖素样肽-1 受体，这是一种经过验证的 G 蛋白偶联受体（GPCR）药物靶点，用于治疗 2 型糖尿病和肥胖症。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Structure Therapeutics</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>Archer Aviation’s Africa Deal Could Boost ACHR Stock</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Are Short Sellers Wrong About These 3 Semiconductor Stocks?</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比结构治疗更好</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>上海证券交易所综合指数是什么？</li>
<li>做空者对这三只半导体股票是否错误？</li>
<li>在 52 周高点盈利交易股票</li>
<li>波音在 3 月份获得 500 亿美元订单——BA 股票现在值得买吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Structure Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在结构治疗公司吗？</h2>
</div><p>Before you consider Structure Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑结构治疗公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前...而结构治疗公司并不在名单上。</p>
</div><p>While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然结构治疗公司目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Structure Therapeutics (NASDAQ:GPCR) 股价上涨 7.5% - 下一步会怎样？